TY - JOUR
T1 - Pitx3 deficiency promotes age-dependent alterations in striatal medium spiny neurons
AU - Chen, Xi
AU - Yang, Zhaofei
AU - Shao, Yaping
AU - Kim, Kunhyok
AU - Wang, Yuanyuan
AU - Wang, Ying
AU - Wu, Haifeng
AU - Xu, Xiaolan
AU - Le, Weidong
N1 - Funding Information:
The youth program of National Natural Science Foundation of China (81901405 to XC), the Key Research and Development Program of Sichuan (2021YFS0382 to XC), and the Key Project of the Medical Science Department, University of Electronic Science and Technology of China (ZYGX2020ZB035 to WL).
Publisher Copyright:
Copyright © 2022 Chen, Yang, Shao, Kim, Wang, Wang, Wu, Xu and Le.
PY - 2022/9/7
Y1 - 2022/9/7
N2 - Background: The classical motor symptoms of Parkinson’s disease (PD) are tightly linked to the gradual loss of dopamine within the striatum. Concomitantly, medium spiny neurons (MSNs) also experience morphological changes, such as reduced dendritic complexity and spine density, which may be potentially associated with motor dysfunction as well. Thus, MSNs may serve as the emerging targets for PD therapy besides the midbrain dopaminergic neurons. Results: To comprehensively examine pathological alterations of MSNs longitudinally, we established a THCre/Pitx3fl/fl (Pitx3cKO) mouse model that developed canonical PD features, including a significant loss of SNc DAergic neurons and motor deficits. During aging, the targeted neurotransmitter, MSNs morphology and DNA methylation profile were significantly altered upon Pitx3 deficiency. Specifically, dopamine, GABA and glutamate decreased in the model at the early stage. While nuclear, soma and dendritic atrophy, as well as nuclear invaginations increased in the aged MSNs of Pitx3cko mice. Furthermore, more nuclear DNA damages were characterized in MSNs during aging, and Pitx3 deficiency aggravated this phenomenon, together with alterations of DNA methylation profiling associated with lipoprotein and nucleus pathway at the late stage. Conclusion: The early perturbations of the neurotransmitters within MSNs may potentially contribute to the alterations of metabolism, morphology and epigenetics within the striatum at the late stage, which may provide new perspectives on the diagnosis and pathogenesis of PD.
AB - Background: The classical motor symptoms of Parkinson’s disease (PD) are tightly linked to the gradual loss of dopamine within the striatum. Concomitantly, medium spiny neurons (MSNs) also experience morphological changes, such as reduced dendritic complexity and spine density, which may be potentially associated with motor dysfunction as well. Thus, MSNs may serve as the emerging targets for PD therapy besides the midbrain dopaminergic neurons. Results: To comprehensively examine pathological alterations of MSNs longitudinally, we established a THCre/Pitx3fl/fl (Pitx3cKO) mouse model that developed canonical PD features, including a significant loss of SNc DAergic neurons and motor deficits. During aging, the targeted neurotransmitter, MSNs morphology and DNA methylation profile were significantly altered upon Pitx3 deficiency. Specifically, dopamine, GABA and glutamate decreased in the model at the early stage. While nuclear, soma and dendritic atrophy, as well as nuclear invaginations increased in the aged MSNs of Pitx3cko mice. Furthermore, more nuclear DNA damages were characterized in MSNs during aging, and Pitx3 deficiency aggravated this phenomenon, together with alterations of DNA methylation profiling associated with lipoprotein and nucleus pathway at the late stage. Conclusion: The early perturbations of the neurotransmitters within MSNs may potentially contribute to the alterations of metabolism, morphology and epigenetics within the striatum at the late stage, which may provide new perspectives on the diagnosis and pathogenesis of PD.
KW - DNA methylation
KW - Parkinson’s disease
KW - aging
KW - medium spiny neurons
KW - neuronal morphology
UR - http://www.scopus.com/inward/record.url?scp=85138424821&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85138424821&partnerID=8YFLogxK
U2 - 10.3389/fnagi.2022.960479
DO - 10.3389/fnagi.2022.960479
M3 - Article
C2 - 36158557
AN - SCOPUS:85138424821
SN - 1663-4365
VL - 14
SP - 960479
JO - Frontiers in Aging Neuroscience
JF - Frontiers in Aging Neuroscience
M1 - 960479
ER -